Thyrocare Technologies Ltd
NSE:THYROCARE
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
559.95
985.8
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Thyrocare Technologies Ltd
Cash from Financing Activities
Thyrocare Technologies Ltd
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Thyrocare Technologies Ltd
NSE:THYROCARE
|
Cash from Financing Activities
-â‚ą848.1m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Dr Agarwal's Eye Hospital Ltd
BSE:526783
|
Cash from Financing Activities
-â‚ą142.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
|
Cash from Financing Activities
-â‚ą3.4B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Vijaya Diagnostic Centre Ltd
NSE:VIJAYA
|
Cash from Financing Activities
-â‚ą445.5m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
N/A
|
||
Krsnaa Diagnostics Ltd
NSE:KRSNAA
|
Cash from Financing Activities
â‚ą841.9m
|
CAGR 3-Years
40%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
||
Metropolis Healthcare Ltd
NSE:METROPOLIS
|
Cash from Financing Activities
-â‚ą1.8B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Thyrocare Technologies Ltd
Glance View
Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 2,115 full-time employees. The company went IPO on 2016-05-09. The firm operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The firm offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The firm offers various kinds of tests, such as Aarogyam X, Aarogyam XL, Aarogyam 1.1, Aarogyam 1.2 and Covid Antibody GT. The company also offers Thyroxine (T4), Triiodothyronine (T3), Thyroid-stimulating hormone and Complete Vitamin Profile tests.
See Also
What is Thyrocare Technologies Ltd's Cash from Financing Activities?
Cash from Financing Activities
-848.1m
INR
Based on the financial report for Jun 30, 2024, Thyrocare Technologies Ltd's Cash from Financing Activities amounts to -848.1m INR.
What is Thyrocare Technologies Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-11%
Over the last year, the Cash from Financing Activities growth was 2%. The average annual Cash from Financing Activities growth rates for Thyrocare Technologies Ltd have been -11% over the past three years .